interstitial lung disease
Conditions
Interventions
None listed
Sponsors
Department of Clinical Research, National Hospital Organization Okayama Medical Center, Okayama, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with pulmonary lesions, such as ground-glass opacities or infiltrative shadows, identified on chest computed tomography (CT), who are scheduled to undergo ultrathin cryobiopsy using a 1.1-mm cryoprobe under a therapeutic bronchoscope to determine the treatment strategy. Age>=20 years. Written informed consent for participation in this study obtained from the patient.
Exclusion criteria
Exclusion criteria: Patients strongly suspected of having lung cancer based on elevated tumor markers in blood tests or imaging findings. Lesions located in the inner one-third of the lung field from the hilum. Patients who require additional bronchoscopic procedures other than bronchoalveolar lavage and cryobiopsy before the examination. Lesions adjacent to major blood vessels. Lesions in which the distance from the planned cryobiopsy site to the pleura is less than 1 cm. Pregnant women or women who may be pregnant. Patients receiving anticoagulant or antiplatelet therapy who cannot discontinue these medications prior to the procedure. Patients with a marked bleeding tendency.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety (bleeding) | — |
Countries
Japan
Contacts
Public ContactYuki Takigawa
NHO Okayama Medical Center IRB
Outcome results
None listed